Home / People / Ruth Mahfoozpour
Portrait of Ruth Mahfoozpour

Ruth Mahfoozpour

Associate for Intellectual Property

CMS Reich-Rohrwig Hainz
Rechtsanwälte GmbH
Gauermanngasse 2
1010 Vienna
Languages German, English, French

Field of activity

Ruth Mahfoozpour works as an associate primarily in the fields of Intellectual Property (IP) and Unfair Competition, Technology, Media & Telecommunications (TMC), and Life Sciences & Healthcare. She joined CMS Reich-Rohrwig Hainz in 2017 and deals especially with litigious mandates in these areas.

Ruth Mahfoozpour advises companies active in the life sciences, media, and consumer goods industries. She advises on issues relating to pharmaceuticals and medical devices, healthcare services, trade secrets, the advertising/marketing of consumer goods, media services, and trademark rights.

Previous work experience / training

During her legal studies at the University of Vienna, Ruth Mahfoozpour worked at the Institute for Civil Procedure Law and later gained experience as an Associate for Dispute Resolution & Litigation. As part of her IP and unfair competition law practice, she regularly handles cases pending before the courts. Ruth Mahfoozpour completed a master's degree at King’s College London (The Dickson Poon School of Law) in 2018/2019 focusing on IP and arbitration.

more less

Memberships & Roles

  • YAAP – Young Austrian Arbitration Practitioners
more less


  • Christian Klausegger/Ruth Mahfoozpour, 10 Years Austrian Yearbook on International Arbitration, in AUSTRIAN YEARBOOK ON INTERNATIONAL ARBITRATION 2016 [311] (Klausegger, Klein, Kremslehner, Petsche, Pitkowitz, Power, Welser & Zeiler, eds., 2016)
more less


  • 2018 - 2019 – Master’s, King’s College London (The Dickson Poon School of Law), LL.M.
  • 2015 - Intern, WKO Strasbourg
  • 2014 - 2015 – Teaching Assistant, University of Vienna, Institute for Civil Procedure Law
more less


Show only
14 December 2020
Di­git­al health apps and telemedi­cine in Aus­tria
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
17 April 2020
Man­dat­ory no­ti­fic­a­tion of sup­ply short­ages of pre­scrip­tion medi­cines
As of April 1st, 2020, mar­ket­ing au­thor­iz­a­tion hold­ers must no­ti­fy to the Aus­tri­an Fed­er­al Of­fice for Safety in Health Care (BASG) if pre­scrip­tion medi­cines are not avail­able or only avail­able in lim­ited...
New re­port­ing ob­lig­a­tion for sup­ply short­ages of pre­scrip­tion medi­cines
Since 1 April 2020, if pre­scrip­tion drugs are not avail­able or only avail­able in lim­ited quant­it­ies, mar­ket­ing au­thor­isa­tion hold­ers have had to no­ti­fy the BASG. Since the new reg­u­la­tion came in­to force...